Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Patterns of medical cannabis use differ between cancer and non-cancer patients

Research published in the Journal of Palliative Medicine has shown that patients with cancer who use medical cannabis tend to prefer a higher or equal ratio of tetrahydrocannabinol to cannabidiol.

medical cannabis ss 18


Patterns of medical cannabis use differ between patients who have cancer and those who do not

Patients with cancer who use medical cannabis to treat symptoms, such as pain and neuropathy, tend to favour formulations with a higher ratio of the psychoactive component, tetrahydrocannabinol (THC), compared with non-cancer patients, a study published in the Journal of Palliative Medicine (25 March 2019) has found[1].

The research looked at data from 11,590 adults, of whom 1,990 had cancer, who were licensed to receive medical cannabis in New York in 2016–2017. The most common qualifying condition in both groups was severe or chronic pain.

The team found that, compared with non-cancer patients, those with cancer were less likely to use a cannabis formulation with a low THC: high cannabidiol (CBD) ratio. Although, over time, the THC:CBD ratio increased in both cancer and non-cancer patients.

THC is the psychoactive component of cannabis and has different medicinal properties to its non-psychoactive counterpart CBD. The researchers suggested that the prevalence of neuropathic pain in cancer patients could be one reason why they tended to favour high or equal THC ratios over low THC: high CBD formulations.

“More research is needed to better understand how different cannabis formulations of THC and CBD may benefit specific conditions or confer risks,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206513

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.